[RESEARCH BLOG] · 2026-10-02

Alumis Inc. (ALMS) – Exhaustion‑Driven Sell Signal in a Crisis Market Regime

By Pierre Brunelle · Founder & Research Lead

ALMSSELLCRISISexhaustion

Alumis Inc. (NASDAQ: ALMS) closed at $6.85, down 4.99 % as of 2026‑10‑02 (Friday, US session). The LOPJLB scanner now flags a SELL directional signal with a ‑3 score, placing the stock in a CRISIS market regime. The confluence of a recent Phase IIb lupus trial miss, widening operating losses and a deteriorating technical outlook has pushed the stock into what our methodology terms “exhaustion.”

Recent News Flow

Alumis’ latest public disclosures have been dominated by the fallout from its systemic lupus erythematosus (SLE) program. Reuters reported on September 1 that the company “eyes late‑stage lupus study despite trial miss”, noting that the Phase IIb LUMUS trial failed to meet its primary efficacy endpoints, but that the firm intends to pursue a larger, late‑stage study focused on a high‑interferon‑signature subgroup.

Seeking Alpha’s September 1 analysis titled “Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside” argued that while the SLE disappointment is material, the company’s psoriasis candidate, envudeucitinib, continues to show a favorable risk‑reward profile in a market with limited TYK2‑inhibitor options.

MarketBeat’s instant alert on the same day highlighted that “Alumis Lupus Trial Misses Main Goals, but High‑Interferon Subgroup Shows Promise”, emphasizing that the subgroup data could sustain investor interest if the subsequent trial confirms efficacy.

Earlier, Alumis presented at Morgan Stanley’s 24th Annual Global Healthcare Conference on September 14, where management outlined a revised development timeline for both the lupus and psoriasis programs and reaffirmed its cash‑burn management plan.

These headlines collectively illustrate a company grappling with a key clinical setback while attempting to leverage its remaining pipeline assets.

Fundamentals and Valuation

Alumis trades at a trailing‑12‑month P/E of –1.80 and an EV/EBITDA of –1.85, reflecting negative earnings and cash‑flow generation. The balance sheet is heavily leveraged, with a debt‑to‑equity ratio of 8.06 and a price‑to‑book of 1.93. Margins are extreme outliers: a gross margin of 88.23 % is offset by an operating margin of –6,204.4 % and a net margin of –5,933.5 %, underscoring that the company’s cost structure far exceeds its revenue base.

Return metrics are equally distressed. ROIC sits at –61.78 %, ROE at –103.0 %, and ROA at –78.30 %, indicating that each dollar of capital employed is eroding value rather than creating it. The discounted cash‑flow (DCF) contribution is 773.5 %, a figure that arises from the model’s reliance on speculative future cash flows rather than current performance.

Analyst sentiment remains surprisingly bullish: the consensus target price is $29.57, and the recommendation is a Buy. This divergence between market price and analyst expectations is reflected in the LOPJLB Value score of 3.00, Growth score of 19.00, GARP score of 5.00, and a modest Quality score of 0.50, placing the stock in the Balanced archetype.

Valuation Snapshot

Metric	Value
P/E (TTM)	–1.80
EV/EBITDA	–1.85
Gross Margin	88.23 %
Net Margin	–5,933.5 %
ROE	–103.0 %
Analyst Target Price	$29.57

Revenue and earnings trends have been volatile. In 2022 the company posted an EPS of ‑$14.93 with free cash flow (FCF) of ‑$110.1 M; 2023 saw EPS improve to ‑$2.99 but FCF worsened to ‑$134.5 M. 2024 reverted to a deeper loss (EPS ‑$10.38, FCF ‑$256.8 M) and 2025 continued the decline with revenue of $24.05 M, EPS ‑$2.32, and FCF ‑$370.2 M. Gross margins have hovered in the mid‑80 % range, yet operating and net margins have remained profoundly negative, reflecting high R&D spend and limited commercial revenue.

The market capitalization of $845.5 M places Alumis among the smaller biotech peers, making it more susceptible to volatility from single‑trial outcomes. The % from high of –77.40 % indicates the stock is trading far below its recent peak, a characteristic often seen in exhaustion phases.

ETF Ownership

Institutional exposure via exchange‑traded funds is modest but concentrated. The three largest ETF holders are:

ETF Ticker	Weight %
XPH	1.50 %
PILL	0.34 %
IHE	0.14 %

Collectively, these funds own roughly 2 % of the float, ranking Alumis at #42‑45 among their holdings. While the absolute exposure is low, the presence of healthcare‑focused ETFs such as XPH (SPDR S&P Pharmaceuticals ETF) and PILL (Invesco Dynamic Pharmaceuticals ETF) can amplify price movements when fund managers rebalance or respond to sector‑wide risk events. In a crisis regime, even modest ETF flows can exacerbate price pressure, especially when technical signals are aligned toward a sell‑off.

LOPJLB Signal Read

The LOPJLB engine currently assigns ALMS a SELL directional signal with a ‑3 composite score, situating the stock in a CRISIS market regime that has persisted for the past 38 days. The PERF composite of –20.40 reflects a steep recent decline, while the FUND quality score of 0.50 signals weak underlying fundamentals. The stock’s archetype is Balanced, blending modest value characteristics (V = 3.0) with high growth expectations (G = 19.0) and a low quality rating.

These metrics suggest that the market has exhausted much of the upside potential that analysts have priced in, and the technical overlays on the interactive chart (exhaustion flags, momentum crossovers, etc.) are aligned with a continued downside bias. Readers are encouraged to explore the interactive chart above for a visual representation of the signal layers, and to review the full LOPJLB methodology for a deeper understanding of how the score and regime are derived.

What’s Next?

Given the Phase IIb lupus trial miss, Alumis will likely focus on enrolling a high‑interferon‑signature cohort for a late‑stage study, a strategy that could restore some investor confidence if early signals prove favorable. Simultaneously, the psoriasis program (envudeucitinib) remains a potential catalyst, especially if the company can demonstrate meaningful efficacy in upcoming Phase III data. However, the substantial operating losses, high leverage, and negative return metrics mean that any upside will require clear, near‑term clinical or commercial milestones.

In the near term, the CRISIS regime and SELL signal suggest that price pressure may continue, particularly if the upcoming lupus subgroup data fails to meet expectations or if broader market risk aversion intensifies. Conversely, a strong subgroup readout or a breakthrough in the psoriasis indication could trigger a rapid re‑rating by analysts, narrowing the gap between the current price and the $29.57 target.